ArticleThe Journal of pharmacology and experimental therapeutics2025
Endothelin-converting enzyme 2 regulates κ opioid receptor trafficking and function.
Article in The Journal of pharmacology and experimental therapeutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Previous studies show that endothelin-converting enzyme 2 (ECE2), an enzyme involved in nonclassical processing of neuropeptide precursors, regulates the rate and extent of μ and δ opioid receptor recycling, but not internalization following activation by select synthetic and endogenous peptidic agonists. This study focuses on κ opioid receptors (KORs) and examines how prodynorphin and proenkephalin-derived peptides that are substrates of ECE2 modulate the internalization and recycling of both KOR and ECE2; as controls we use peptides that are not ECE2 substrates. First, we use a proximity-based ligation assay to show that KOR and ECE2 are in close proximity to directly interact and cointernalize. Treatment with the peptides induces internalization and recycling of ECE2 at a rate and extent comparable to that of KOR with longer opioid peptides inducing fast and robust internalization and recycling of both ECE2 and KOR compared with shorter peptides. We find that in recombinant cell lines and naïve cells expressing endogenous receptors, a small molecule ECE2 inhibitor attenuates KOR recycling as well as signaling by only peptides that are ECE2 substrates. Taken with the differential expression of ECE2 in the brain (relatively high expression in midbrain and dentate gyrus of the hippocampus and low expression in the striatum), these results highlight a pivotal role for ECE2 in differentially modulating KOR function. SIGNIFICANCE STATEMENT: This study highlights a role for endothelin-converting enzyme 2 in agonist mediated regulation of κ opioid receptor function by select prodynorphin and proenkephalin-derived peptides. Collectively, studies by authors suggest that endothelin-converting enzyme 2 inhibitors could be developed as therapeutics for pathologies involving dysregulations in κ opioid receptor signaling.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.